Effector-to-Target (E:T) Cytotoxicity: Single-Cell Secretion vs. Standard Chromium Release

Establishing the functional potency of cellular immunotherapies requires measuring the active cytotoxic machinery deployed by effector cells upon encountering cognate tumor antigens. Conventional cytotoxicity assays present significant operational and biological limitations: legacy radioactive Chromium-51 (51Cr) Release assays pose severe radiation hazards and measure only late-stage target cell membrane rupture; non-radioactive lactate dehydrogenase (LDH) or bioluminescent luciferase release assays measure bulk population averages that fail to quantify the exact frequency of functional, cytotoxic effector cells.

Granzyme B and IFN-γ ELISpot / FluoroSpot captures cytotoxic mediator secretion directly at the single-cell interface during effector-to-target (E:T) co-culture. Because Granzyme B is released exclusively upon immunologic synapse formation with target cells, enumerating Granzyme B spot-forming units (SFU) provides a direct, highly sensitive, and non-radioactive measurement of antigen-specific killer T-cell frequency.

Key Strengths of Granzyme B and IFN-γ Single-Cell Potency Testing

  • Direct Cytotoxic Granule Release: Quantifies single-cell secretion of Granzyme B and Perforin, the primary enzymatic mediators of target cell apoptosis, rather than relying solely on indirect cytokine surrogates.
  • Dual Effector & Cytolytic Deconvolution: Multi-color FluoroSpot simultaneously measures Granzyme B (direct killing) alongside IFN-γ (immunomodulatory activation) in the same microplate well.
  • Ultra-Sensitive Effector Frequency: Detects cytotoxic killing at low Effector-to-Target (E:T) ratios (e.g., 1:1, 1:5, 1:10), conserving precious clinical-grade cell therapy batches.
  • Antigen-Specific Target Verification: Testing against target-positive versus target-negative (isogenic control) tumor lines confirms strict antigen-dependent activation and eliminates non-specific allogeneic background.